Page last updated: 2024-08-22

camptothecin and Cancer of Ovary

camptothecin has been researched along with Cancer of Ovary in 279 studies

Research

Studies (279)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.36)	18.7374
1990's	75 (26.88)	18.2507
2000's	106 (37.99)	29.6817
2010's	90 (32.26)	24.3611
2020's	7 (2.51)	2.80

Authors

Authors	Studies
al-Said, NH; Lown, JW; Sternbach, DL; Zhao, R	1
Burgess, JP; Fairchild, CR; Farnsworth, NR; Kinghorn, AD; Navarro, HA; Oberlies, NH; Peterson, RW; Pinos, RE; Soejarto, DD; Wall, ME; Wani, MC	1
Chai, HB; Fan, Z; Fong, HH; Pezzuto, JM; Sun, H; Tan, GT; Zhang, H	1
Animati, F; Berettoni, M; Bigioni, M; Binaschi, M; Cipollone, A; Irrissuto, C; Nardelli, F; Olivieri, L	1
Burdette, JE; Fuchs, JR; Mize, BK; Ren, Y; Salvi, A	1
Cookson, E	1
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y	1
Bagley, S; Brison, DR; Edmondson, RJ; Lucena, E; Medina-Sánchez, M; Nelson, L; Restrepo, LP; Ribeiro, C; Schmidt, CK; Schmidt, OG; Seaton, MPH; Taylor, SS; Xu, H; Zeng, K; Zhang, W	1
Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS	1
An, HJ; Cho, YB; Ghosh, M; Hong, SD; Hur, J; Kang, M; Katuwal, NB; Kim, TH; Moon, YW; Pandey, K; Park, N	1
Birrer, MJ; Campos, SM; Chadda, KR; D'Ascanio, AM; Horowitz, NS; Konstantinopoulos, PA; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Young, CL	1
Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ	1
Chiba, Y; Fukagawa, D; Itamochi, H; Kawamura, H; Kojima-Chiba, A; Muraki, Y; Sato, S; Suga, Y; Sugai, T; Sugiyama, T; Yoshino, N	1
Bruckner, HW; Gurell, D; Hirschfeld, A	1
Cincinelli, R; Dallavalle, S; De Santis, R; Giannini, G; Minenkova, O; Musso, L; Santapaola, D; Vesci, L	1
Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD	1
Beckert, S; Horvath, P; Königsrainer, A; Königsrainer, I; Nadalin, S	1
Ganeshaiah, KN; Kumar, TR; Priti, V; Ramesha, BT; Ravikanth, G; Senthilkumar, U; Shaanker, RU; Suma, HK; Vasudeva, R	1
Arakawa, A; Itani, Y; Ito, K; Kawaguchi, R; Shiozaki, T; Tabata, T; Takeuchi, S; Toyoda, S; Tsubamoto, H	1
Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Tsutsui, T; Ueda, Y; Yoshino, K	1
Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J	1
Liu, JL; Palakurthi, S; Vangara, KK	1
Goto, S; Kamigaki, T; Saito, M; Yano, K	1
Furuya, K; Goto, T; Hirata, J; Horie, K; Kikuchi, Y; Kino, N; Kudoh, K; Takahashi, M; Takano, M; Yokota, H	1
Fujiwara, K; Katakami, N; Kitao, A; Matsumoto, K; Minami, H; Morita, S; Negoro, S; Shibata, N; Tanioka, M; Yamaguchi, S	1
Enomoto, T; Fujita, M; Kimura, T; Miyatake, T; Nagamatsu, M; Nishio, Y; Tsutsui, T; Ueda, Y; Yamasaki, M; Yoshino, K	1
Duvillard, P; Gouy, S; Lhomme, C; Morice, P; Pautier, P; Uzan, C	1
Burtness, B; Chun, YS; Cohen, SJ; Hall, MJ; Nagorney, DM; Sigurdson, ER; Thomay, AA; Truty, MJ	1
Boige, V; Borget, I; Caramella, C; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Farron, M; Goéré, D; Honoré, C; Malka, D; Pottier, E	1
Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Passot, G; Roux, AS; Vaudoyer, D	1
Chaudhury, A; Chiu, GN; Liu, Y; Shaikh, IM; Tan, BJ; Tan, BM; Tan, KB	1
Ali, HI; Kolluru, S; Liu, JL; Lu, D; Palakurthi, S; Vangara, KK	1
Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P	1
Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ	1
Fujimori, K; Kaido, Y; Kaiho, M; Mizunuma, H; Nishiyama, H; Omi, H; Otsuki, T; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Yaegashi, N; Yokoyama, Y	1
Guo, LD; Jia, YG; Liu, C; Lou, JY; Wang, S; Wang, X; Yang, J	1
Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y	1
Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T	1
Berek, JS; Chung, YM; Guan, M; Hu, MC; Hu, T; Ma, J; Ma, M	1
Asahara, H; Ishikawa, T; Itamochi, H; Kigawa, J; Kuroki, M; Manabe, S; Miyamoto, S; Miyata, K; Nam, SO; Odawara, T; Takada, S; Yotsumoto, F	1
Chen, M; Chen, Z; Li, X; Liu, C; Luo, X; Yuan, J; Zhao, Y	1
Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ	1
Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T	1
Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Nakamura, K; Saitou, M; Satoh, T; Shibata, T; Takano, T; Yunokawa, M	1
Kamei, T; Miwa, I; Nakamura, Y; Sakamoto, Y; Shinagawa, M	1
Bai, J; Bian, Z; Chen, F; Fu, S; Guan, R; Jin, Y; Quan, C; Sun, W; Wu, J; Xu, L; Yu, Y	1
Birrer, MJ; Eliasof, S; Garmey, EG; Kerbel, RS; Krasner, C; Lazarus, D; Lee, CR; Man, S; Matulonis, UA; Peters, CG; Pham, E; Xu, P	1
Bai, H; Liu, Y; Ma, N; Ren, Z; Wang, F; Xu, S	1
Ding, YY; Song, LX; Xu, JF; Xu, Q	1
Fukagawa, S; Katsuda, T; Kondo, H; Maehara, M; Miyahara, D; Miyamoto, S; Miyata, K; Nam, SO; Ueda, T	1
An, HW; Chen, CL; Chen, CS; Cheng, KT; Huang, SH; Hwang, J; Lee, CH; Lee, CM; Lee, YC; Leiw, PL; Lin, CM; Tsai, HP; Wu, JC	1
Dartigues, P	1
Gjerset, RA; Zhao, M	1
Chen, H; Chen, X; Cheng, X; Gou, L; Li, W; Su, X; Wang, Y; Wei, X; Wei, Y; Wu, Y; Xie, Y; Yang, J; Yao, Y; Yu, L; Zhang, B; Zhang, H; Zhang, R; Zhang, Y	1
Auzolle, C; Bonnetain, F; Bouché, O; Brieau, B; Coriat, R; Ducreux, M; Goujon, G; Lecomte, T; Marthey, L; Pozet, A; Prieux, C; Rougier, P; Soibinet, P; Taieb, J; Tougeron, D; Zaanan, A	1
Chiba, Y; Chikumi, J; Harada, T; Itamochi, H; Komatsu, H; Kudoh, A; Nonaka, M; Oishi, T; Oumi, N; Sato, S; Shimada, M; Sugiyama, T	1
Alexandre, J; Aoki, D; Aotani, E; Enomoto, T; Fujiwara, K; Green, J; Hamano, T; Isonishi, S; Kato, K; Kim, BG; Kim, JW; Mikami, M; Nishino, K; Nomura, H; Okamoto, A; Pignata, S; Sugiyama, T; Suzuki, N; Tanabe, H; Terao, Y; Terauchi, F; Yaegashi, N; Yokoyama, Y; Yoshikawa, H	1
Blank, SV; Boyd, L; Curtin, J; Goldberg, JD; Li, X; Ling, HT; Muggia, F; Musa, F; Pothuri, B; Speyer, JL; Tiersten, A	1
Li, S; Tian, H; Wu, J; Yao, D; Zhu, X	1
Akahane, T; Aoki, D; Hirasawa, A; Kataoka, F; Mushiroda, T; Nanki, Y; Nomura, H; Susumu, N; Tominaga, E; Yamagami, W; Yoshihama, T	1
Fukai, H; Ichikawa, G; Kita, E; Kuwana, Y; Matsumoto, H; Nakayama, Y; Ohta, Y; Takami, M; Takimoto, T; Yamamoto, T	1
al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW	1
Kanazawa, T; Matsubara, M; Matsushita, K; Mukohara, Y; Nozaki, A; Oka, H; Tokumitsu, S; Tsunashima, T	1
Grènman, S; Miettinen, S; Ylikomi, T	1
Akira, S; Li, L; Tanaka, T; Umesaki, N; Yukawa, K	1
Fujiwara, K; Furuya, K; Goto, T; Hirata, J; Horie, K; Ishii, K; Kato, M; Kikuchi, Y; Kino, N; Kita, T; Sasaki, N; Takahashi, M; Takano, M; Yokota, H; Yoshikawa, T	1
Chen, G; Di, W; Xia, L; Yu, Y; Zhang, H; Zhang, N; Zheng, Y; Zhu, Y	1
Bae, J; Kim, YJ; Lee, CS; Lee, SJ	1
Miettinen, S; Ylikomi, T	1
Amanze, A; Di Federico, E; Taylor, J; Verschraegen, C	1
Han, SS; Kang, SB; Kim, HS; Kim, JW; Lee, HP; Park, NH; Seo, SS; Song, YS	1
Jang, SY; Jung, YW; Kim, JH; Kim, JW; Kim, S; Kim, SW; Kim, YT; Lee, DW; Nam, EJ	1
Barbieri, P; Brienza, S; Carminati, P; Colombo, N; du Bois, A; Frigerio, L; Guastalla, JP; Katsaròs, D; Lhommé, C; Lissoni, AA; Parma, G; Pecorelli, S; Poveda, A; Ray-Coquard, I; Tisi, G; Tredan, O; Vermorken, JB	1
Aulicino, C; Bargiotti, A; Bucci, F; Castorina, M; Dal Pozzo, A; Dallavalle, S; Esposito, E; Foderà, R; Giannini, G; Musso, L; Ni, MH; Penco, S; Pisano, C; Vesci, L	1
Bello, E; Carminati, P; Compagnoni, A; D'Incalci, M; Frapolli, R; Locatelli, A; Marsoni, S; Pisano, C; Rulli, E; Sessa, C; Viganò, L; Zucchetti, M	1
Ishizuka, B; Kiguchi, K; Kobayashi, Y; Kondo, H; Ohara, T; Suzuki, N; Yahagi, N	1
Kawasaki, N; Maeda, Y; Nakamura, M; Nishimura, T; Okada, T; Sakata, K; Setoguchi, M	1
Benedetti, V; Zuco, V; Zunino, F	1
Aoki, D; Inaba, N; Noda, K; Ochiai, K; Saito, T; Sugiyama, T; Takahashi, F; Takakura, S; Takano, M	1
Chung, HH; Kang, S; Kang, SB; Kim, HS; Kim, JW; Park, NH; Seo, SS; Song, YS	1
Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P	1
Ajmi, S; Ben Ahmed, S; Ben Fatma, L; Ben Hadj Hamida, R; Braham, A; Chabchoub, I; Gahbiche, S; Gharbi, O; Hochlef, M; Landolsi, A; Letaief, R; Limam, S; Mokni, M	1
Guo, G; Kong, X; Li, X; Luo, F; Qian, Z; Shi, S; Wang, Y; Wei, Y; Zhang, J; Zhao, X	1
Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, SW; Nam, JH	1
Choi, KC; Jeung, EB; Kim, KY; Kim, SU; Leung, PC	1
Chen, X; Du, L; He, X; Li, X; Li, Z; Qian, Z; Wei, Y; Wen, Y; Zhao, X; Zhou, L	1
Chen, JH; Lai, CL; Lai, L; Zhao, JB	1
Fan, M; Murdoch, WJ; Radosz, M; Shen, Y; Sui, M; Tang, J; Van Kirk, EA; Xu, P; Zhou, Z	1
Mizutani, K; Nako, Y; Nei, T; Ozaki, Y; Wakana, K; Yasugi, T	1
Asami, S; Idani, F; Kin, H; Komoto, S; Kubo, S; Kubota, T; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yoshioka, T	1
Fujimoto, T; Kumagai, S; Kurachi, H; Mizunuma, H; Nakahara, K; Nishiyama, H; Omi, H; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Tase, T; Yaegashi, N; Yokoyama, Y; Yoshizaki, A	1
Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW	1
Bae, DS; Choi, CH; Kim, BG; Kim, MK; Kim, TJ; Lee, JH; Lee, JW; Lee, YY; Park, HS; Song, TJ	1
Futagami, M; Hakamada, K; Hirakawa, H; Mizunuma, H; Yokoyama, Y	1
Chen, DY; Qi, Q; Zhao, WY	1
Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L	1
Hata, Y; Honda, K; Ihara, E; Ihara, Y; Misawa, T; Miyata, S; Sumida, Y; Tomita, Y	1
Ota, T; Takeshima, N; Takizawa, K	1
Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K	1
Hwang, JH; Kang, S; Lim, MC; Park, SY; Seo, SS; Yoo, HJ	1
Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K	1
Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Miyoshi, Y; Morimoto, A; Ueda, Y; Yokoyama, T; Yoshino, K	1
Fukuda, H; Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Saito, I; Shibata, T	1
Huang, H; Li, H; Liu, JH	1
Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K	1
Aoki, D; Chiyoda, T; Kataoka, F; Nomura, H; Susumu, N; Tominaga, E; Tsuda, H; Yamagami, W	1
Furuya, K; Goto, T; Kato, M; Miyamoto, M; Sasaki, N; Takano, M	1
Kunito, S; Nagata, C; Ochiai, K; Okamoto, A; Saito, M; Sasaki, H; Takakura, S; Tanaka, T; Yamada, K; Yanaihara, N	1
Granot, T; Meruelo, D	1
Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T	1
Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L	1
Kaneda, N; Konishi, H; Kurita, A; Matsuzaki, T; Takagi, A	1
Berger, A; Brieau, B; Dubreuil, O; Landi, B; Lepère, C; Markoutsaki, T; Rougier, P; Roussel, H; Taieb, J; Trouilloud, I; Vaillant, JN; Zaanan, A	1
Gershenson, DM	1
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH	2
Lalloo, A; Minko, T; Paranjpe, PV; Qiu, B; Sinko, PJ; Stein, S; Won, R	1
Hasegawa, K; Hiura, M; Ikeda, M; Ishikawa, M; Kamura, T; Kikkawa, F; Noda, K; Ochiai, K; Ohashi, Y; Saji, F; Sato, S; Sugiyama, T; Takahashi, T; Takeuchi, S; Umesaki, N; Yakushiji, M	1
Boven, E; Erkelens, CA; Pinedo, HM; Schlüper, HM; Tohgo, A; van Hattum, AH	1
Boven, E; Hoogsteen, IJ; Kohlhagen, G; Maliepaard, M; Pinedo, HM; Pommier, Y; Scheffer, GL; Scheper, RJ; Schlüper, HM; van Hattum, AH	1
Fujii, H; Konishi, M; Koshiyama, M; Tauchi, K; Yoshida, M	1
Kawano, Y; Miyakawa, I; Narahara, H; Nasu, K; Takai, N; Utsunomiya, H	1
Inoue, S; Kagawa, M; Kusanishi, H; Watanabe, Y	1
Bodurka, DC; Gano, J; Gershenson, DM; Kavanagh, JJ; Levenback, C; Wharton, JT; Wolf, JK	1
Kanishi, Y; Kiguchi, K; Kobayashi, Y; Kondo, H; Okuma, Y; Saito, K; Sato, S	1
Noda, K; Ochiai, K; Sugiyama, T; Yakushiji, M	1
Belinson, J; Markman, M; Rose, P; Webster, K; Zanotti, K	1
Ishihara, A; Nagao, K; Tanaka, H; Toyoda, N; Umekawa, T	1
Arzani, D; Carbone, E; Cesario, A; Margaritora, S; Russo, P; Valente, P	1
Pizzolato, JF; Saltz, LB	1
Balan, KV; Han, Z; Hu, X; Pantazis, P; Ramos-DeSimone, N; Wyche, JH	1
Dharap, SS; Minko, T; Qiu, B; Sinko, P; Stein, S; Williams, GC	1
Aghajanian, C; Dizon, DS; Hensley, M; Hummer, A; Leitao, MM; Sabbatini, P; Spriggs, DR; Venkatraman, E	1
Bukowski, R; Canetta, R; Ganapathi, R; Grabowski, D; Lee, F; Markman, M; Mekhail, T; Peck, R; Takigawa, N; Uyar, D	1
Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M	1
Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T	1
Akiyama, T; Doi, T; Hirata, K; Homma, H; Iyama, S; Kida, M; Kogawa, K; Mezawa, S; Murakami, K; Murase, K	1
Hirano, T; Kubo, H; Masaki, K; Ogura, H; Taoka, H; Terauchi, F; Yamamoto, Y	1
Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J	1
Belinson, J; Escobar, PF; Markman, M; Rose, P; Webster, K; Zanotti, K	1
Cammia, C; Croci, V; De Nicolao, G; Germani, M; Magni, P; Pesenti, E; Poggesi, I; Rocchetti, M; Simeoni, M	1
Astrow, A; Barrett, E; Campos, S; Matulonis, U; Muggia, F; Roche, M; Rusk, J; Seiden, MV; Sivret, J	1
Isonishi, S; Niimi, S; Ochiai, K; Sasaki, H; Tanaka, T; Yasuda, M	1
Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H	1
Boiocchi, M; Campagnutta, E; Cecchin, E; Corona, G; Martella, L; Russo, A; Toffoli, G	1
Adams, M; Atkinson, R; Boven, E; Calvert, AH; Cervantes, A; Cheverton, P; Clamp, A; Ganesan, T; Jayson, GC; Lotz, J; Vasey, P	1
Bjornsti, MA; de Jong, LA; Jansen, LE; Pluim, D; Schellens, JH; van Eijndhoven, MA; van Waardenburg, RC; Verseyden, C	1
Bergottini, R; De Cesare, M; Pratesi, G; Veneroni, S; Zunino, F	1
Hatae, M; Nakamura, T; Onishi, Y	1
Ichikawa, Y; Nishida, M; Tsunoda, H; Yoshikawa, H	1
Bagella, L; D'Andrilli, G; Gabellini, C; Giordano, A; Masciullo, V; Romano, G; Scambia, G; Tonini, T; Zupi, G	1
Blessing, JA; Bloss, J; Miller, DS; Schilder, J; Schilder, R; Sorosky, J; Waggoner, S	1
Aoki, Y; Fujita, K; Kurata, H; Tanaka, K; Watanabe, M	1
Sugiyama, T	1
Barrett, E; Calvert, AH; Cameron, T; Coleman, R; Dark, GG; Eisenhauer, EA; Ellard, S; Grimshaw, R; Hamilton, M; Jayson, G; Kaye, S; Le, T; McIntosh, L; Poole, C; Swenerton, K; Trudeau, M; Vasey, P; Walsh, W	1
de Graaf, M; Gerritsen, WR; Giaccone, G; Haisma, HJ; Oosterhoff, D; Overmeer, RM; Pinedo, HM; van Beusechem, VW; van der Meulen, IH	1
Boutis, LL; Geromichalos, GD; Kalemi, TG; Kortsaris, AH; Kotsis, A; Lambropoulos, AF; Papazisis, KT; Zambouli, D	1
Amikura, T; Aoki, Y; Fujita, K; Nishino, K; Obata, H; Sekine, M; Tanaka, K; Yahata, T	1
Fujiwara, Y; Kasamatsu, T; Katsumata, N; Tsunematsu, R; Yamada, T; Yamamoto, N; Yonemori, K	1
Akiba, Y; Hibi, T; Higuchi, H; Iizuka, H; Izumiya, M; Nagata, H; Takaishi, H; Yamagishi, Y	1
Balasubramanian, BN; Fairchild, CR; Jang, GR; Long, B; Marathe, PH; Monticello, TM; Rose, WC; Wall, ME; Wani, MC	1
Andoh, M; Fujiwara, Y; Katsumata, N; Kohno, T; Matsumoto, K; Shimizu, C; Yamanaka, Y; Yonemori, K	1
Clark, JW	1
Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM	1
Chandna, P; Khandare, JJ; Minko, T; Pozharov, VP; Wang, Y	1
Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W	1
Bae, JM; Choi, IJ; Chun, JH; Kim, CG; Kim, HK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW; Yu, MS	1
Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W	1
Ishihara, A; Kihira, T; Nomura, Y; Tanaka, H	1
Ishiguro, A; Kudo, T; Mitobe, S; Munakata, M; Okada, R; Sakata, Y; Shitara, K; Tomioka, R; Yokoyama, S	1
Kigawa, J; Kikuchi, Y; Kuzuya, K; Moriya, T; Sagae, S; Sugiyama, T; Suzuki, M; Takano, M; Takeuchi, S; Tsuda, H; Udagawa, Y; Yaegashi, N	2
Brocheriou, I; Deray, G; Izzedine, H; Rixe, O	1
Kanamori, T; Kawashima, T; Murakami, H; Nakamura, Y	1
Jobo, T	1
Kamura, T; Kitagawa, R; Nishio, S; Shouji, T; Sugiyama, T; Ushijima, K; Yoshizaki, A	1
Egorin, MJ; Eiseman, JL; Joseph, E; Parise, RA; Strychor, S; Zamboni, WC	1
Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K	1
Bang, YJ; Kang, SB; Kim, JH; Lee, HP; Lee, KH; Nam, JH; Park, SY; Ryu, SY; Seo, SS; Song, YS	1
Inagaki, D; Katayama, K; Oosawa, H; Shiraishi, R; Tanabe, H; Tani, K; Wada, H; Yasuda, S	1
Tanaka, T; Umesaki, N; Utsunomiya, H; Utsunomiya, T	1
Aulicino, C; Benedetti, V; Bucci, F; Carminati, P; De Cesare, M; Foderà, R; Penco, S; Pisano, C; Vesci, L; Zuco, V; Zunino, F	1
Herzog, TJ; Wethington, SL; Wright, JD	1
Hanabayashi, T; Itoh, M; Itoh, N; Misao, R; Mori, H; Morishita, S; Murase, T; Niwa, K; Tamaya, T	1
Atsumi, R; Hakusui, H; Okazaki, O	1
Funayama, Y; Isogai, Y; Kanzawa, F; Kuraishi, Y; Lee, YS; Nishio, K; Ogasawara, H; Ohira, T; Saijo, N	1
Higashide, K; Kikkawa, F; Maeda, O; Misawa, T; Obata, NH; Suganuma, N; Tomoda, Y	1
Corti, C; Giardini, R; Pratesi, G; Tortoreto, M; Zunino, F	1
Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T	1
Furue, H	1
Early, JA; Giovanella, BC; Hinz, HR; Kozielski, AJ; Mendoza, JT; Pantazis, P	1
Hata, K; Higuchi, M; Kajino, T; Shibata, N	1
Besterman, JM; Croom, DK; Emerson, DL; Evans, MG; Lackey, K; Leitner, PL; Luzzio, MJ; McIntyre, G; Sternbach, DD; Vuong, A; Yates, J	1
Terada, K	1
Chantarawiroj, P; Edwards, CL; Freedman, RS; Gonzalez de Leon, C; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Levenback, C; Madden, T; Raber, M; Tresukosol, D; Verschraegen, C; Wallin, B	1
Beijnen, JH; Creemers, GJ; Davies, B; de Boer-Dennert, M; McDonald, M; Rosing, H; Schellens, JH; Verweij, J	1
Sinha, BK; Wang, Z	1
Smith, CD; Zhang, X	1
Fields, AL; Goldberg, GL; Runowicz, CD	1
Beijnen, JH; Creemers, GJ; Davies, BE; de Boer-Dennert, M; Maes, RA; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ; Verweij, J	1
Barnett, AA	1
Hasumi, K; Shimizu, Y; Umezawa, S	3
Catimel, G; Talon, A	1
Hasuo, Y; Imaishi, K; Kataoka, A; Komai, K; Nishida, T; Ookura, N; Sugiyama, T; Ushijima, K; Yakushiji, M	1
Cimoli, G; Debernardis, D; Parodi, S; Russo, P	1
Tomida, A; Tsuruo, T; Yun, J	1
Eisenhauer, EA; Vermorken, JB	1
Hassan, R; Kohn, E; Sandor, V	1
Bolis, G; Creemers, GJ; Despax, R; Favalli, G; Gore, M; Guastalla, JP; Hudson, I; Kreinberg, R; Lacave, AJ; Scarfone, G; Ten Bokkel Huinink, WW; Van Belle, S; Verweij, J	1
Arbuck, SG; Dimery, I; Muggia, FM	1
Broom, C	1
Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR	1
Fojo, AT; Hwang, J; Lo, CK; Mickley, LA; Su, JS; Ting, CY; Wang, LF; Whang-Peng, J	1
Markman, M	1
Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W	1
Dunton, CJ	1
Janik, JE; Saltz, L	1
Heuser, A; Sauer, R	1
Ozols, RF	1
Bolis, G; Broom, C; Carmichael, J; Coleman, R; Davidson, N; Fields, SC; Gordon, A; Gore, M; Heron, JF; Hudson, I; Malfetano, J; Malmström, H; Scarabelli, C; Spanczynski, M; ten Bokkel Huinink, W	1
Shimizu, Y	1
Bolis, G; Despax, R; Gore, M; Gwyther, S; Hudson, IR; Jiménez-Lacave, A; ten Bokkel Huinink, W; Verweij, J	1
Koarai, N; Kobayashi, A; Sugizaki, N; Yamaguchi, M	1
Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM	1
Boven, E; Erkelens, CA; Jansen, WJ; Kolfschoten, GM; Pinedo, HM; Van Ark-Otte, J	1
Astoul, C; Ollitrault, N; Salvat, D	1
Harstrick, A; Hilger, RA; Rustum, YM; Seeber, S; Vanhoefer, U; Voigt, W; Yin, MB	1
Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y	1
Agrawal, S; Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; Jiang, Z; Pepe, S; Pomatico, G; Tortora, G	1
Kolker, HJ; Loos, WJ; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J	1
Kigawa, J; Nishida, T; Okura, N; Sugiyama, T; Terakawa, N; Ushijima, K; Yakushiji, M	1
Rosen, LS	1
Brown, R; McDonald, AC	1
O'meara, AT; Sevin, BU	1
Ames, MM; Aytes, SA; Kuffel, MJ; Lineswala, JP; Zembower, DE; Zhang, H	1
Edwards, CL; Freedman, RS; Giovanella, BC; Gupta, E; Harris, N; Kavanagh, JJ; Kudelka, AP; Loyer, E; Steger, M; Stehlin, JS; Steltz, V; Verschraegen, CF	1
de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC	1
Kigawa, J; Minagawa, Y; Oishi, T; Sugiyama, T; Takahashi, M; Terakawa, N; Yakushiji, M	1
Chen, AY; Choy, H; Rothenberg, ML	1
Adachi, S; Kanazawa, R; Koyama, K; Ogasawara, T; Shibahara, H; Takemura, T; Tsuji, Y; Yamasaki, N	1
Kamura, T; Sugiyama, T; Ushijima, K	1
Ogita, S; Tanaka, T; Umesaki, N	1
Saltz, LB	1
Boven, E; Hoogsteen, I; Pinedo, HM; Schlüper, HM; Van Hattum, AH	1
Downey, A; Hamilton, A; Hochster, H; Hornreich, G; Liebes, L; Muggia, F; Potmesil, M; Sorich, J; Wasserstrom, H	1
Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW	1
Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J	1
Shen, K; Sun, Z; Xu, X	1
Learned, J	1
Arimoto, Y; Hayashi, S; Komura, H; Kunishige, I; Okuno, Y; Otsuki, Y; Shimoya, K	1
Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z	1
Bucci, F; Capocasa, F; Carenini, N; Carminati, P; De Cesare, M; Merlini, L; Pace, S; Penco, S; Perego, P; Pisano, C; Pratesi, G; Tinelli, S; Vesci, L; Zunino, F	1
Aoki, D; Komuro, Y; Kubota, T; Nozawa, S; Susumu, N; Udagawa, Y	1
Azevedo, P; Deavers, MT; Freedman, RS; Kavanagh, JJ; Kudelka, AP; Lu, K; Verschraegen, CF	1
Itamochi, H; Kigawa, J; Minagawa, Y; Terakawa, N	1
Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T	1
Fujimura, M; Fushiki, H; Izumi, R; Nakashima, A; Saito, S; Yuuki, H	1
Fukai, H; Idei, T; Matsumoto, H; Nakayama, Y; Ohta, H; Sakamoto, H; Satoh, K; Takami, M; Togo, Y; Yamamoto, T	1
Boyd, G; Cummings, J; Jodrell, DI; Macpherson, JS; Smith, G; Smyth, JF; Wolf, H	1
Kohno, T; Mizukami, H; Ozawa, K; Saga, Y; Sato, I; Suzuki, M; Urabe, M	1
Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N	1
Chen, BM; Chern, JW; Leu, YL; Prijovich, ZM; Roffler, SR	1
de Bruijn, P; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Verweij, J	1
Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Hurowitz, LA; Kaufmann, SH; Lubejko, BG; McGuire, WP; Rowinsky, EK; Sartorius, SE	1
Cimoli, G; Conte, P; Conzi, G; Noviello, E; Orengo, G; Pagnan, G; Parodi, S; Russo, P; Schenone, F; Venturini, M	1
Fujiwara, Y; Nakagawa, K; Niimi, S; Nishio, K; Saijo, N; Sugimoto, Y; Terashima, Y; Yokoyama, S	1
Hawkins, MJ	1
Akiya, K; Dobashi, K; Fujimoto, S; Hasumi, K; Negishi, Y; Suzuki, M; Takeuchi, S; Tamaya, T; Tanaka, K; Terashima, Y	1
Noda, K; Ohkawa, T; Sekiba, K; Sugawa, T; Taguchi, T; Takamizawa, H; Takeda, Y; Takeuchi, S; Tamaya, T; Yakushiji, M	1
Andrews, PA; Howell, SB; Katz, EJ; Kling, KM; Vick, JS	1
Chen, SC; Inoue, K; Itoh, Y; Ogawa, M; Shibata, H; Wang, Y	1

Reviews

32 review(s) available for camptothecin and Cancer of Ovary

Article	Year
Discovery and development of botanical natural products and their analogues as therapeutics for ovarian cancer. Natural product reports, 2023, 07-19, Volume: 40, Issue:7 Topics: Biological Products; Camptothecin; Female; Humans; Ovarian Neoplasms	2023
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2 Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea	2022
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma]. Annales de pathologie, 2015, Volume: 35, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms	2015
Irinotecan in epithelial ovarian cancer. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Irinotecan; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Topoisomerase I Inhibitors	2002
Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects. Cancer detection and prevention, 2002, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Treatment Outcome	2002
Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma. Archives of gynecology and obstetrics, 2002, Volume: 267, Issue:2 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Resistance; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retreatment	2002
Japanese ovarian trials: focus on irinotecan. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:5 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Japan; Ovarian Neoplasms; United States; Women's Health	2003
The camptothecins. Lancet (London, England), 2003, Jun-28, Volume: 361, Issue:9376 Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Structure-Activity Relationship; Topoisomerase I Inhibitors	2003
[Treatment of platinum-resistant ovarian cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome	2004
[Second-line chemotherapy for recurrent ovarian cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids	2005
Rubitecan. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors	2006
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	2008
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1994
[Irinotecan hydrochloride (CPT-11)]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Leukemia L1210; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms	1994
[Development of new anti-cancer agents in Europe]. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Europe; Female; France; Humans; Irinotecan; Japan; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms	1996
Promising new therapies in the treatment of advanced ovarian cancer. Cancer, 1995, Nov-15, Volume: 76, Issue:10 Suppl Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan	1995
New drugs in gynecologic oncology. Current opinion in oncology, 1996, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Platinum Compounds; Uterine Cervical Neoplasms	1996
Camptothecin and its analogs. An overview of their potential in cancer therapeutics. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Female; Hematologic Neoplasms; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Uterine Neoplasms	1996
Clinical studies of topotecan. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan	1997
New options for the treatment of advanced ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1997
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
[Topoisomerase I inhibitor with potential radiosensitizing effect]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1997, Volume: 173, Issue:3 Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan	1997
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 1 Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Transitional Cell; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms	1997
[A case of solitary metastatic splenic tumor of ovarian carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Hysterectomy; Irinotecan; Ovarian Neoplasms; Splenectomy; Splenic Neoplasms	1997
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. Antisense & nucleic acid drug development, 1998, Volume: 8, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Division; Cisplatin; Colonic Neoplasms; Combined Modality Therapy; Cyclic AMP-Dependent Protein Kinases; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Fluorouracil; Genetic Therapy; Humans; Methotrexate; Oligonucleotides, Antisense; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Thionucleotides; Tumor Cells, Cultured; Vincristine	1998
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6 Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms	1998
DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan	1999
[New regimens for the treatment of gynecologic cancers]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms	2000
Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Parenteral; Neoplasms; Ovarian Neoplasms; Topoisomerase I Inhibitors	2000
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer. Human cell, 2001, Volume: 14, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; HeLa Cells; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured	2001
New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles. Oncology (Williston Park, N.Y.), 1992, Volume: 6, Issue:12 Topics: Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Ovarian Neoplasms; Paclitaxel	1992

Trials

65 trial(s) available for camptothecin and Cancer of Ovary

Article	Year
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2 Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea	2022
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecologic oncology, 2021, Volume: 162, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Ovarian Epithelial; Cyclodextrins; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms	2021
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). British journal of cancer, 2017, Jun-27, Volume: 117, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting	2017
Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330). Anticancer research, 2013, Volume: 33, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms	2013
UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study. European journal of gynaecological oncology, 2013, Volume: 34, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms	2013
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4 Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Carboplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Endometrial Neoplasms; Female; Granisetron; Humans; Irinotecan; Logistic Models; Middle Aged; Morpholines; Neoplasms; Ovarian Neoplasms; Temperance; Treatment Outcome; Vomiting	2013
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study). European journal of obstetrics, gynecology, and reproductive biology, 2013, Volume: 170, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids	2013
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols	2014
Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503). Gynecologic oncology, 2015, Volume: 136, Issue:2 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Young Adult	2015
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Feb-15, Volume: 21, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cyclodextrins; Drug Synergism; Female; Humans; Mice; Mice, SCID; Nanoparticles; Ovarian Neoplasms; Xenograft Model Antitumor Assays	2015
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Survival Rate; Taxoids; Treatment Outcome	2015
The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial. Anticancer research, 2015, Volume: 35, Issue:8 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Treatment Outcome	2015
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-20, Volume: 34, Issue:24 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate	2016
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. Gynecologic oncology, 2017, Volume: 144, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms	2017
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Annals of surgical oncology, 2009, Volume: 16, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Mesothelioma; Middle Aged; Mitomycin; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate	2009
Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer. Annals of the New York Academy of Sciences, 2009, Volume: 1171 Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Epithelial Cells; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Treatment Outcome	2009
Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. American journal of clinical oncology, 2010, Volume: 33, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome	2010
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Recurrence; Taxoids	2010
Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Blood Specimen Collection; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Mice; Mice, Nude; Middle Aged; Orosomucoid; Ovarian Neoplasms; Xenograft Model Antitumor Assays; Young Adult	2010
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome	2010
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study). International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2011
Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer, 2011, May-15, Volume: 117, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms	2011
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult	2011
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study. International journal of clinical oncology, 2013, Volume: 18, Issue:1 Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids	2013
Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer. Anti-cancer drugs, 2012, Volume: 23, Issue:3 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Thrombocytopenia; Treatment Outcome	2012
Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:3 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Ovarian Neoplasms; Research Design; Taxoids	2012
Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology, 2002, Volume: 63, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prospective Studies; Treatment Outcome	2002
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-15, Volume: 21, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Camptothecin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms	2003
Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:5 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Women's Health	2003
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan	2004
Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. International journal of clinical oncology, 2003, Volume: 8, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome	2003
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome	2004
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic oncology, 2004, Volume: 92, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms	2004
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Ovarian Neoplasms; Topotecan	2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Topoisomerase I Inhibitors	2004
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecologic oncology, 2005, Volume: 96, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms	2005
Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. American journal of clinical oncology, 2004, Volume: 27, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Pilot Projects	2004
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Canada; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms	2005
Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecologic oncology, 2005, Volume: 97, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Prospective Studies	2005
A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer, 2005, Sep-15, Volume: 104, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms	2005
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. British journal of cancer, 2006, Jan-16, Volume: 94, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2006
Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. British journal of cancer, 2006, May-22, Volume: 94, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids	2006
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. British journal of cancer, 2006, May-22, Volume: 94, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate	2006
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2006, Volume: 12, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Japan; Mitomycin; Ovarian Neoplasms; Pilot Projects; Salvage Therapy; Uterine Cervical Neoplasms	2006
Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecologic oncology, 2007, Volume: 106, Issue:2 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pilot Projects; Taxoids	2007
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecologic oncology, 2008, Volume: 109, Issue:3 Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Topoisomerase I Inhibitors	2008
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan	1996
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. British journal of cancer, 1996, Volume: 73, Issue:10 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Carcinoma, Small Cell; Colonic Neoplasms; Cross-Over Studies; Female; Humans; Hydroxy Acids; Lactones; Male; Metabolic Clearance Rate; Middle Aged; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1996
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3 Topics: Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	1996
[Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C]. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:5 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Remission Induction; Survival Rate	1996
[Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer]. Nihon Sanka Fujinka Gakkai zasshi, 1996, Volume: 48, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms	1996
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelium; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan	1996
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting	1997
[Topotecan--a new principle of effectiveness in oncology. 4th Salzburg Symposium on Quality of Life. 15-17 December 1995]. Geburtshilfe und Frauenheilkunde, 1996, Volume: 56, Issue:6 Suppl Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan	1997
Experience with independent radiological review during a topotecan trial in ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Middle Aged; Ovarian Neoplasms; Tomography, X-Ray Computed; Topotecan	1997
Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecologic oncology, 1997, Volume: 66, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome	1997
Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer letters, 1998, Jun-19, Volume: 128, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms	1998
A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Annals of the Academy of Medicine, Singapore, 1998, Volume: 27, Issue:5 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Survival Rate; Time Factors	1998
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anti-cancer drugs, 1999, Volume: 10, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Rate	1999
A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Japanese journal of clinical oncology, 1999, Volume: 29, Issue:9 Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Pilot Projects	1999
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan	2000
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan	1992
[A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers]. Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Ovarian Neoplasms; Uterine Cervical Neoplasms	1991
[An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers]. Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Uterine Neoplasms	1991

Other Studies

183 other study(ies) available for camptothecin and Cancer of Ovary

Article	Year
Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro. Journal of medicinal chemistry, 1997, Jan-17, Volume: 40, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; HT29 Cells; Humans; KB Cells; Netropsin; Ovarian Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1997
Novel bioactive clerodane diterpenoids from the leaves and twigs of Casearia sylvestris. Journal of natural products, 2002, Volume: 65, Issue:2 Topics: Antifungal Agents; Antineoplastic Agents, Phytogenic; Aspergillus niger; Colonic Neoplasms; Diterpenes; Drug Screening Assays, Antitumor; Ecuador; Female; Humans; Inhibitory Concentration 50; KB Cells; Lung Neoplasms; Magnoliopsida; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Ovarian Neoplasms; Plant Leaves; Plant Shoots; Plants, Medicinal; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Tumor Cells, Cultured	2002
Pseudoirroratin A, a new cytotoxic ent-kaurene diterpene from Isodon pseudo-irrorata. Journal of natural products, 2002, Volume: 65, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Diterpenes; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Female; Humans; Inhibitory Concentration 50; KB Cells; Lamiaceae; Lung Neoplasms; Male; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Osteosarcoma; Ovarian Neoplasms; Plants, Medicinal; Prostatic Neoplasms; Spectrophotometry, Ultraviolet; Stereoisomerism; Tumor Cells, Cultured	2002
Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety. Bioorganic & medicinal chemistry letters, 2012, Aug-01, Volume: 22, Issue:15 Topics: Animals; Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Female; Humans; Imides; Mice; Ovarian Neoplasms; Structure-Activity Relationship; Transplantation, Heterologous	2012
2020 ASCO Annual Meeting. The Lancet. Haematology, 2020, Volume: 7, Issue:7 Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cholangiocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Female; Humans; Immunoconjugates; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Societies, Medical; Trastuzumab; Urinary Bladder Neoplasms	2020
Human spermbots for patient-representative 3D ovarian cancer cell treatment. Nanoscale, 2020, Oct-15, Volume: 12, Issue:39 Topics: Animals; Camptothecin; Cattle; Doxorubicin; Drug Delivery Systems; Female; Humans; Male; Ovarian Neoplasms; Sperm Motility	2020
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan	2020
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer. International journal of molecular sciences, 2021, Jan-27, Volume: 22, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Immunohistochemistry; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Ovarian Neoplasms; Phosphorylation; Pyrimidines; Sulfonamides; Sulfoxides; Xenograft Model Antitumor Assays	2021
Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:8 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Immunohistochemistry; Irinotecan; Ki-67 Antigen; M Phase Cell Cycle Checkpoints; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tissue Array Analysis	2017
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer. Anticancer research, 2018, Volume: 38, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids	2018
Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative. Bioorganic & medicinal chemistry letters, 2018, 11-01, Volume: 28, Issue:20 Topics: Animals; Antineoplastic Agents; Avidin; Biotin; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Ovarian Neoplasms; Protein Binding	2018
Acquired resistance to immunotherapy in MMR-D pancreatic cancer. Journal for immunotherapy of cancer, 2018, 11-20, Volume: 6, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Camptothecin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Oxaliplatin; Pancreatic Neoplasms	2018
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors. Journal of visceral surgery, 2019, Volume: 156, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Fluorouracil; Hepatectomy; Humans; Hyperthermia, Induced; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies	2019
New plant sources of the anti-cancer alkaloid, camptothecine from the Icacinaceae taxa, India. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2013, Apr-15, Volume: 20, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Magnoliopsida; Ovarian Neoplasms; Phytotherapy; Plant Extracts; Seeds	2013
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids	2013
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:5 Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia	2013
Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer. Anticancer research, 2013, Volume: 33, Issue:6 Topics: Animals; Biological Transport; Camptothecin; Cell Line, Tumor; CHO Cells; Cricetinae; Drug Carriers; Emulsions; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Nanoparticles; Ovarian Neoplasms; Particle Size; Polyethylene Glycols; Polyglactin 910; Topoisomerase I Inhibitors	2013
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). Anticancer research, 2013, Volume: 33, Issue:7 Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium	2013
Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors. European journal of obstetrics, gynecology, and reproductive biology, 2013, Volume: 170, Issue:2 Topics: Adult; Antineoplastic Agents; Camptothecin; Female; Granulosa Cell Tumor; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Retrospective Studies; Treatment Outcome	2013
Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2014, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Young Adult	2014
Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2013, Volume: 39, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Tomography, X-Ray Computed	2013
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Pseudomyxoma Peritonei; Quality of Life; Stomach Neoplasms; Treatment Outcome	2014
Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft. Journal of controlled release : official journal of the Controlled Release Society, 2013, Dec-28, Volume: 172, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Humans; Irinotecan; Liposomes; Manganese; Mice; Mice, SCID; Ovarian Neoplasms; Ovary	2013
SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer. AAPS PharmSciTech, 2014, Volume: 15, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cyclodextrins; Female; Humans; Irinotecan; Ovarian Neoplasms; Solubility	2014
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis, 2014, Volume: 17, Issue:3 Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome	2014
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2014, Volume: 18, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusion; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Gallbladder Neoplasms; Humans; Hyperthermia, Induced; Intraoperative Care; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Stomach Neoplasms; Survival Rate; Tertiary Care Centers	2014
[DNA damage response of epithelial ovarian cancer cells (primary culture) to chemo-radiotherapy]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2014, Volume: 45, Issue:2 Topics: Camptothecin; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Culture Media; DNA Breaks, Double-Stranded; Female; Histones; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Signal Transduction; Tumor Cells, Cultured; X-Rays	2014
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. Archives of gynecology and obstetrics, 2014, Volume: 290, Issue:5 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome	2014
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:5 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured	2014
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. Scientific reports, 2014, Jul-24, Volume: 4 Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Irinotecan; Metformin; Mice, Nude; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Tumor Burden; Xenograft Model Antitumor Assays	2014
Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma. Cancer medicine, 2014, Volume: 3, Issue:5 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heparin-binding EGF-like Growth Factor; Humans; Irinotecan; Ovarian Neoplasms; Promoter Regions, Genetic; Protein Binding; Sp1 Transcription Factor	2014
Folate-decorated and reduction-sensitive micelles assembled from amphiphilic polymer-camptothecin conjugates for intracellular drug delivery. Molecular pharmaceutics, 2014, Nov-03, Volume: 11, Issue:11 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Lactones; Micelles; Molecular Structure; Ovarian Neoplasms; Polyethylene Glycols; Surface Properties; Tissue Distribution; Tumor Cells, Cultured	2014
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer. Yonsei medical journal, 2014, Volume: 55, Issue:6 Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids	2014
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:11 Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence	2014
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan. The journal of obstetrics and gynaecology research, 2015, Volume: 41, Issue:5 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Retreatment; Treatment Outcome	2015
RPL13A as a reference gene for normalizing mRNA transcription of ovarian cancer cells with paclitaxel and 10-hydroxycamptothecin treatments. Molecular medicine reports, 2015, Volume: 11, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Computational Biology; Female; Gene Expression Profiling; Humans; Ovarian Neoplasms; Paclitaxel; Ribosomal Proteins; RNA Stability; RNA, Messenger; Transcription, Genetic	2015
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer. Genetics and molecular research : GMR, 2015, Jun-29, Volume: 14, Issue:2 Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Cisplatin; Diarrhea; DNA-Binding Proteins; Endonucleases; Female; Gene Expression; Gene Frequency; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polymorphism, Genetic; Treatment Outcome	2015
Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer. PloS one, 2015, Volume: 10, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Indole Alkaloids; Mice; Ovarian Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays	2015
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker. PloS one, 2015, Volume: 10, Issue:8 Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan	2015
Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates. Journal of controlled release : official journal of the Controlled Release Society, 2015, Dec-28, Volume: 220, Issue:Pt A Topics: Animals; Camptothecin; Cell Line, Tumor; Female; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays	2015
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Epirubicin; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovariectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Young Adult	2016
Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression. Human cell, 2016, Volume: 29, Issue:4 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromosomes; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Deletion; Gene Expression; Humans; Irinotecan; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Transcription Factors	2016
Tumor-cell targeting polydiacetylene micelles encapsulated with an antitumor drug for the treatment of ovarian cancer. Chemical communications (Cambridge, England), 2017, Jan-19, Volume: 53, Issue:7 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Lysosomes; Mice; Micelles; Molecular Structure; Neoplasms, Experimental; Ovarian Neoplasms; Polyacetylene Polymer; Polymers; Polyynes; Structure-Activity Relationship	2017
UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan. Japanese journal of clinical oncology, 2017, 02-04, Volume: 47, Issue:2 Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Polymorphism, Genetic; Prognosis	2017
[A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:7 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Radiography	2008
[A case of ovarian cancer in which a remarkable effect was seen with intrathoracic administration of CDDP and CPT-11]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Injections; Irinotecan; Middle Aged; Ovarian Neoplasms; Thorax; Tomography, X-Ray Computed	2008
Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Anti-cancer drugs, 2009, Volume: 20, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; G2 Phase; Gene Expression Regulation; Humans; Irinotecan; Ovarian Neoplasms; Taxoids	2009
Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase. International journal of oncology, 2009, Volume: 34, Issue:4 Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Death-Associated Protein Kinases; Fas Ligand Protein; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Granulosa Cells; Humans; Irinotecan; Mice; Mice, Inbred C57BL; Models, Biological; Ovarian Follicle; Ovarian Neoplasms; Ovary	2009
Clinical significance of UDP-glucuronosyltransferase 1A16 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology, 2009, Volume: 76, Issue:5* Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Risk Factors; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult	2009
NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells. Cancer letters, 2009, Jun-18, Volume: 278, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ovarian Neoplasms; Protein Kinase C-delta	2009
Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines. Chemico-biological interactions, 2009, Oct-07, Volume: 181, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; Enzyme Activators; Enzyme-Linked Immunosorbent Assay; Female; Guanylate Cyclase; Humans; Indazoles; Neoplasm Proteins; Ovarian Neoplasms	2009
Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy. Anti-cancer drugs, 2009, Volume: 20, Issue:7 Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Combined Modality Therapy; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Ovarian Neoplasms; Taxoids; Tumor Suppressor Protein p53	2009
Irinotecan use during pregnancy. Obstetrics and gynecology, 2009, Volume: 114, Issue:2 Pt 2 Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Care	2009
Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation. Bioorganic & medicinal chemistry, 2010, Jan-01, Volume: 18, Issue:1 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Humans; Mice; Mice, Nude; Molecular Structure; Oligopeptides; Ovarian Neoplasms	2010
[Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms	2009
[Ovarian metastasis after complete response of colon cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Hysterectomy; Leucovorin; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy	2009
ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968. Cancer letters, 2010, Jun-28, Volume: 292, Issue:2 Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Female; Humans; Infrared Rays; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Ultraviolet Rays	2010
Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. The journal of obstetrics and gynaecology research, 2010, Volume: 36, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Epithelium; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan	2010
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Molecular cancer therapeutics, 2010, Volume: 9, Issue:4 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays	2010
[Prognostic factors and survival of metastatic colorectal cancer in the Sousse University Hospital (Tunisia): comparative study of two treatment period of 200 patients]. Bulletin du cancer, 2010, Volume: 97, Issue:4 Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tunisia; Young Adult	2010
A novel composite hydrogel based on chitosan and inorganic phosphate for local drug delivery of camptothecin nanocolloids. Journal of pharmaceutical sciences, 2011, Volume: 100, Issue:1 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chemical Phenomena; Chemistry, Pharmaceutical; Chitosan; Colloids; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Stability; Female; Humans; Hydrogels; Kinetics; Mice; Mice, Inbred BALB C; Nanostructures; Ovarian Neoplasms; Phosphates	2011
The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome	2010
Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer science, 2010, Volume: 101, Issue:4 Topics: Animals; Antimetabolites; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cell Line, Tumor; Cytosine Deaminase; Female; Flucytosine; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Ovarian Neoplasms; Prodrugs; Stem Cells	2010
The antitumor and antimetastatic effects of N-trimethyl chitosan-encapsulated camptothecin on ovarian cancer with minimal side effects. Oncology reports, 2010, Volume: 24, Issue:4 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Chitosan; Disease Models, Animal; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays	2010
[Synthesis of polyrotaxane-camptothecin conjugates and evaluation of its anti-tumor effect]. Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cyclodextrins; Drug Carriers; Drug Compounding; Female; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Ovarian Neoplasms; Poloxamer; Rotaxanes; Sarcoma 180; Tumor Burden	2010
Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery. Nanomedicine (London, England), 2010, Volume: 5, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Nucleus; Dendrimers; Drug Carriers; Female; Fluorescein-5-isothiocyanate; Humans; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Neoplasms; Ovarian Neoplasms; Polyamines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2010
Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura. International journal of clinical oncology, 2011, Volume: 16, Issue:4 Topics: Adenocarcinoma, Clear Cell; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Postoperative Period; Purpura, Thrombocytopenic, Idiopathic	2011
[A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur	2010
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:1 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult	2011
[Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed	2011
Novel activity of acriflavine against colorectal cancer tumor cells. Cancer science, 2011, Volume: 102, Issue:12 Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Female; Fluorouracil; High-Throughput Screening Assays; Humans; Irinotecan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	2011
[A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:9 Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Panitumumab; Sigmoid Neoplasms	2011
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly? European journal of gynaecological oncology, 2011, Volume: 32, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids	2011
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. International journal of clinical oncology, 2013, Volume: 18, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids	2013
Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel. Anticancer research, 2011, Volume: 31, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome	2011
[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms]. Zhonghua fu chan ke za zhi, 2011, Volume: 46, Issue:12 Topics: Adult; Alleles; Amplified Fragment Length Polymorphism Analysis; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Uterine Cervical Neoplasms	2011
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids	2012
Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer. European journal of gynaecological oncology, 2012, Volume: 33, Issue:1 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Mucositis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy	2012
Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary. International journal of clinical oncology, 2013, Volume: 18, Issue:3 Topics: Adenocarcinoma, Clear Cell; Camptothecin; Deoxycytidine; Female; Humans; Male; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Taxoids	2013
Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy. The journal of obstetrics and gynaecology research, 2012, Volume: 38, Issue:12 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Japan; Laparotomy; Middle Aged; Ovarian Neoplasms; Proportional Hazards Models; Retrospective Studies; Second-Look Surgery	2012
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan. Cancer gene therapy, 2012, Volume: 19, Issue:8 Topics: Animals; Camptothecin; Female; Humans; Irinotecan; Killer Cells, Natural; Mice; Mice, SCID; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Sindbis Virus; Topoisomerase Inhibitors	2012
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers. European journal of gynaecological oncology, 2012, Volume: 33, Issue:3 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids	2012
Camptothecins in tumor homing via an RGD sequence mimetic. Bioorganic & medicinal chemistry letters, 2012, Oct-15, Volume: 22, Issue:20 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats	2012
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse. BMC cancer, 2012, Oct-10, Volume: 12 Topics: Animals; Antineoplastic Agents; Ascites; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Female; Humans; Irinotecan; Liposomes; Mice; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Xenograft Model Antitumor Assays	2012
Chemosensitivity in ovarian metastases from gastric cancer: a case series. Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms	2013
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. International journal of cancer, 2002, Jul-01, Volume: 100, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	2002
Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptotic Protease-Activating Factor 1; Biological Transport; Biotinylation; Camptothecin; Carrier Proteins; Caspases; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Membrane Glycoproteins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Polyethylene Glycols; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Solubility; Symporters; Tumor Cells, Cultured	2002
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochemical pharmacology, 2002, Oct-15, Volume: 64, Issue:8 Topics: Animals; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Division; Cisplatin; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Sulfhydryl Reagents; Tetraspanin 29; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Xenograft Model Antitumor Assays	2002
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. British journal of cancer, 2002, Sep-09, Volume: 87, Issue:6 Topics: Acridines; Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Isoquinolines; Membrane Glycoproteins; Mice; Mice, Nude; Mutation; Neoplasm Proteins; Neoplasms, Experimental; Ovarian Neoplasms; Tetrahydroisoquinolines; Tetraspanin 29; Tetrazolium Salts; Thiazoles; Topoisomerase I Inhibitors; Tumor Cells, Cultured	2002
[A case of ovarian cancer in which a remarkable effect was seen with low-dose CDDP intratumoral injection of CPT-11]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cystadenocarcinoma, Papillary; Drug Therapy, Combination; Female; Humans; Injections, Intralesional; Injections, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritonitis	2002
Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary. Human cell, 2002, Volume: 15, Issue:3 Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Culture Techniques; Cell Division; Cisplatin; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Karyotyping; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Ovarian Neoplasms; Tumor Cells, Cultured	2002
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports. European journal of gynaecological oncology, 2003, Volume: 24, Issue:3-4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Sampling Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2003
TNF increases camptothecin-induced apoptosis by inhibition of NF-kappaB. European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA; Female; Flow Cytometry; Humans; NF-kappa B; Ovarian Neoplasms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2003
Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC. Anti-cancer drugs, 2003, Volume: 14, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Transformation, Neoplastic; Clone Cells; Female; Flow Cytometry; Genes, bcl-2; Humans; Ovarian Neoplasms; Tumor Cells, Cultured	2003
Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. Journal of controlled release : official journal of the Controlled Release Society, 2003, Aug-28, Volume: 91, Issue:1-2 Topics: Amino Acids; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; DNA Primers; Drug Carriers; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; Microscopy, Fluorescence; Ovarian Neoplasms; Ovary; Peptide Fragments; Pharmaceutical Vehicles; Polyethylene Glycols; Proto-Oncogene Proteins; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured	2003
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecologic oncology, 2003, Volume: 91, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Retrospective Studies	2003
Apoptotic pathways of epothilone BMS 310705. Gynecologic oncology, 2003, Volume: 91, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cytochrome c Group; Drug Resistance, Neoplasm; Enzyme Activation; Epothilones; Female; Humans; Irinotecan; Isoenzymes; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured	2003
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms	2003
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Ovarian Neoplasms; Prognosis; Quality of Life; Skin Neoplasms; Stomach Neoplasms	2003
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer research, 2004, Feb-01, Volume: 64, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Models, Biological; Ovarian Neoplasms; Paclitaxel	2004
Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Irinotecan; Lymph Node Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies	2004
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer. Oncology reports, 2004, Volume: 12, Issue:2 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome	2004
UGT1A128 polymorphism in ovarian cancer patients. Oncology reports, 2004, Volume: 12, Issue:2* Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Estrogens; Female; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Loss of Heterozygosity; Odds Ratio; Ovarian Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Protein Isoforms; Regression Analysis	2004
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. The Journal of biological chemistry, 2004, Dec-24, Volume: 279, Issue:52 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cisplatin; Colonic Neoplasms; Cytarabine; DNA; DNA Adducts; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Female; Humans; Models, Molecular; Ovarian Neoplasms; Platinum Compounds; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2004
Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-01, Volume: 10, Issue:21 Topics: Animals; Brain; Camptothecin; Female; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Nervous System Neoplasms; Ovarian Neoplasms; Time Factors; Xenograft Model Antitumor Assays	2004
Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma. International journal of clinical oncology, 2004, Volume: 9, Issue:5 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Parity; Treatment Outcome	2004
pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-01, Volume: 10, Issue:23 Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Flow Cytometry; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Proteins; Retinoblastoma Protein; Retinoblastoma-Like Protein p130; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2004
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. British journal of cancer, 2005, Mar-14, Volume: 92, Issue:5 Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Irinotecan; Ovarian Neoplasms	2005
Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro. Cancer letters, 2006, Feb-28, Volume: 233, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cells, Cultured; Drug Synergism; Female; Fibroblasts; G2 Phase; Genistein; HeLa Cells; Humans; In Vitro Techniques; Ovarian Neoplasms; Phosphorylation; Protein-Tyrosine Kinases	2006
[A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:8 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Krukenberg Tumor; Lymphangitis; Ovarian Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur	2005
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:1 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Nude; Ovarian Neoplasms; Prodrugs; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays	2006
The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecologic oncology, 2006, Volume: 100, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Taxoids	2006
Novel polymeric prodrug with multivalent components for cancer therapy. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 317, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Design; Female; Gonadotropin-Releasing Hormone; Humans; Molecular Structure; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Polymers; Prodrugs; Rats; Xenograft Model Antitumor Assays	2006
Expression of drug pathway proteins is independent of tumour type. The Journal of pathology, 2006, Volume: 209, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis	2006
[Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:10 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Diseases; Cisplatin; Colonoscopy; Drainage; Drug Administration Schedule; Fatal Outcome; Female; Humans; Intestinal Perforation; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pleural Effusion, Malignant	2006
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncology reports, 2006, Volume: 16, Issue:6 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome	2006
Thrombotic microangiopathy and anti-VEGF agents. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:5 Topics: Biopsy; Camptothecin; Drug Therapy, Combination; Female; Humans; Irinotecan; Kidney Glomerulus; Middle Aged; Ovarian Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Thrombosis; Vascular Endothelial Growth Factor A	2007
[A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; CA-125 Antigen; Camptothecin; Carcinoma, Endometrioid; Cisplatin; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Laparotomy; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids	2007
[Outpatient chemotherapy in gynecologic oncology]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 2 Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Female; Humans; Irinotecan; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms; Uterine Neoplasms	2006
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. International journal of clinical oncology, 2007, Volume: 12, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis	2007
Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Docetaxel; Female; Humans; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Ovarian Neoplasms; Taxoids; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays	2008
Carbon beam therapy in recurrent ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy	2008
[Multiple hepatic metastases and ovarian metastases of colon cancer responding to combined therapy with S-1 and CPT-11--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed	2008
Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women. Oncology reports, 2008, Volume: 19, Issue:5 Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Ovary; Perimenopause; Premenopause; Primary Ovarian Insufficiency; Treatment Outcome; Uterine Cervical Neoplasms	2008
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:9 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured	2008
Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative. Japanese journal of cancer research : Gann, 1994, Volume: 85, Issue:8 Topics: Adenocarcinoma; Base Sequence; Blotting, Southern; Camptothecin; Cell Line; DNA Primers; DNA Topoisomerases, Type I; DNA, Neoplasm; Endometrial Neoplasms; Female; Gene Expression; HeLa Cells; Humans; Molecular Sequence Data; Ovarian Neoplasms; Polymerase Chain Reaction; Restriction Mapping; RNA-Directed DNA Polymerase; RNA, Messenger; Tumor Cells, Cultured	1994
Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model. Biological & pharmaceutical bulletin, 1995, Volume: 18, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma 256, Walker; Cattle; Chromatography, High Pressure Liquid; Female; Irinotecan; Ovarian Neoplasms; Rats; Rats, Wistar; Tumor Cells, Cultured	1995
Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Japanese journal of cancer research : Gann, 1995, Volume: 86, Issue:1 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA; Drug Resistance; Drug Resistance, Multiple; Duocarmycins; Female; Humans; Irinotecan; Lung Neoplasms; Microsomes; Ovarian Neoplasms; Pyrrolidinones; Tumor Cells, Cultured	1995
Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells. Japanese journal of cancer research : Gann, 1995, Volume: 86, Issue:1 Topics: Camptothecin; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance; Drug Resistance, Multiple; Etoposide; Female; Glutathione; Glutathione Transferase; Humans; Ovarian Neoplasms; Tumor Cells, Cultured	1995
Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. British journal of cancer, 1995, Volume: 71, Issue:3 Topics: Animals; Antineoplastic Agents; Biotransformation; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Topotecan; Transplantation, Heterologous	1995
Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. International journal of cancer, 1993, Mar-12, Volume: 53, Issue:5 Topics: Animals; Camptothecin; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured	1993
[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Thrombocytopenia	1996
Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin. Journal of medicinal chemistry, 1996, Feb-02, Volume: 39, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Ovarian Neoplasms; Solubility; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water	1996
Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo. Molecular pharmacology, 1996, Volume: 49, Issue:2 Topics: Animals; Antineoplastic Agents; Biological Transport; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Nucleus; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Female; Humans; Interleukin-1; Irinotecan; Mice; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Protein Biosynthesis; Recombinant Proteins; Transcription, Genetic; Transplantation, Heterologous	1996
Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Molecular pharmacology, 1996, Volume: 49, Issue:2 Topics: Alkaloids; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colchicine; Cyanobacteria; Cytoskeleton; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance, Multiple; Etoposide; Female; GTP Phosphohydrolases; Humans; Indole Alkaloids; Kinetics; Microtubules; Muscle, Smooth, Vascular; Ovarian Neoplasms; Tubulin	1996
FDA approve bark-derived drug. Lancet (London, England), 1996, Jun-08, Volume: 347, Issue:9015 Topics: Antineoplastic Agents; Camptothecin; Drug Approval; Female; Humans; Ovarian Neoplasms; Topotecan; United States; United States Food and Drug Administration	1996
[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary]. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:7 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms	1996
[Ovarian cancer. The new chemotherapeutic agents]. Soins; la revue de reference infirmiere, 1995, Issue:599 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Topotecan	1995
Trial of topotecan as first-line treatment for ovarian cancer announced. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Topotecan	1996
Topotecan approved for cancer chemotherapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Aug-01, Volume: 53, Issue:15 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Topotecan	1996
Interactions between taxol and camptothecin. Anti-cancer drugs, 1996, Volume: 7, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Drug Antagonism; Female; Humans; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured	1996
Glucose-regulated stresses induce resistance to camptothecin in human cancer cells. International journal of cancer, 1996, Nov-04, Volume: 68, Issue:3 Topics: Antineoplastic Agents, Alkylating; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Female; Glucose; HSP70 Heat-Shock Proteins; HT29 Cells; Humans; Membrane Proteins; Ovarian Neoplasms; Stress, Physiological; Tumor Cells, Cultured	1996
Topotecan hydrochloride for metastatic ovarian cancer. The Medical letter on drugs and therapeutics, 1996, Oct-25, Volume: 38, Issue:986 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Ovarian Neoplasms; Topotecan	1996
Exacerbation of pseudogout by granulocyte colony-stimulating factor. Annals of internal medicine, 1996, Nov-01, Volume: 125, Issue:9 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Chondrocalcinosis; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Humans; Ovarian Neoplasms; Recombinant Proteins; Recurrence	1996
Hycamtin achieves promising results in study of patients with leukemia. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ovarian Neoplasms; Remission Induction; Topotecan	1996
Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer research, 1997, Apr-15, Volume: 57, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Humans; Mutagenesis; Mutation; Neoplasm Proteins; Ovarian Neoplasms; Polymerase Chain Reaction; Transfection; Tumor Cells, Cultured; Yeasts	1997
Second-line therapy. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 1997, Feb-12, Volume: 11, Issue:21 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan; Treatment Failure	1997
Topotecan: an important new drug in the management of ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	1997
Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. International journal of cancer, 1997, Dec-10, Volume: 73, Issue:6 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Messenger; Sarcoma; Sarcoma, Experimental; Tumor Cells, Cultured	1997
[Derivatives of camptothecin. A new class of antineoplastic agents]. Soins; la revue de reference infirmiere, 1997, Issue:621 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Ovarian Neoplasms; Topotecan	1997
Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multid Oncology research, 1997, Volume: 9, Issue:9 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blotting, Northern; Camptothecin; Carbazoles; Cell Count; Chromatography, High Pressure Liquid; DNA Topoisomerases, Type I; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fibrosarcoma; Glucosides; Humans; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1997
[Evaluation of a new anti-cancer drug regimen for surface epithelial-stromal ovarian cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:5 Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured	1998
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. British journal of cancer, 1998, Volume: 77, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line; Cross Reactions; Drug Resistance; Enzyme Inhibitors; Female; Glucose; Humans; Irinotecan; Kinetics; Ovarian Neoplasms; Temperature; Topoisomerase I Inhibitors; Topotecan	1998
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. British journal of cancer, 1998, Volume: 78, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	1998
In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan). Gynecologic oncology, 1999, Volume: 72, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Flow Cytometry; Humans; In Vitro Techniques; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors	1999
Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110. Bioorganic & medicinal chemistry letters, 1999, Jan-18, Volume: 9, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Carbazoles; Female; Glucosides; HT29 Cells; Humans; Inhibitory Concentration 50; Male; Ovarian Neoplasms; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1999
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer research, 1999, Sep-15, Volume: 59, Issue:18 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured	1999
Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer. International journal of cancer, 1999, Oct-22, Volume: 84, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms	1999
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. International journal of cancer, 2000, Oct-15, Volume: 88, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2000
Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases. European journal of gynaecological oncology, 2000, Volume: 21, Issue:4 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mitomycin; Ovarian Neoplasms; Peritoneal Neoplasms	2000
Irinotecan: a new agent comes of age. The oncologist, 2001, Volume: 6, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Humans; International Cooperation; Irinotecan; Male; Ovarian Neoplasms; Uterine Cervical Neoplasms	2001
New analogues of camptothecins. Activity and resistance. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2000
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2000
[The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro]. Zhonghua fu chan ke za zhi, 1999, Volume: 34, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured	1999
Topotecan and PML: the limits of pharmaceutical industry research. Notes from the underground (New York, N.Y.), 1996, Issue:No 33 Topics: AIDS-Related Opportunistic Infections; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Consumer Advocacy; Drug Approval; Drug Evaluation, Preclinical; Drug Industry; Health Services Accessibility; HIV Infections; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Ovarian Neoplasms; Topotecan	1996
[A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:6 Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Cisplatin; Cyclophosphamide; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome	2001
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum. Journal of natural products, 2001, Volume: 64, Issue:7 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine	2001
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer research, 2001, Oct-01, Volume: 61, Issue:19 Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001
Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin. Japanese journal of cancer research : Gann, 2001, Volume: 92, Issue:11 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Cell Division; Cisplatin; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Irinotecan; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Ouabain; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured	2001
Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. European journal of gynaecological oncology, 2001, Volume: 22, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Mixed Tumor, Mesodermal; Ovarian Neoplasms; Remission Induction; Topoisomerase I Inhibitors	2001
[Globalization of anti-cancer therapies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms	2002
[Apoptosis as a measure of chemosensitivity to anti-cancer drugs in gynecological cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Female; Humans; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Neoplasms	2002
[A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinosarcoma; Cisplatin; Drug Administration Schedule; Female; Humans; Hysterotomy; Irinotecan; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms	2002
Factors influencing the cellular accumulation of SN-38 and camptothecin. Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:3 Topics: Adenocarcinoma; Biological Transport; Camptothecin; Colonic Neoplasms; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Genes, MDR; Humans; Irinotecan; Kinetics; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured	2002
Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Female; Gene Expression; Genetic Vectors; Humans; Inhibitory Concentration 50; Irinotecan; Ovarian Neoplasms; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sequence Analysis, DNA; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins	2002
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:6 Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured	2002
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. British journal of cancer, 2002, May-20, Volume: 86, Issue:10 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Stability; Female; Glucuronides; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Prodrugs; Sex Factors; Solubility; Topotecan; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays	2002
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. British journal of cancer, 2002, Jul-15, Volume: 87, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prodrugs; Random Allocation; Tumor Cells, Cultured; Uterine Cervical Neoplasms	2002
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation. Japanese journal of cancer research : Gann, 1992, Volume: 83, Issue:11 Topics: Camptothecin; Cell Death; Cisplatin; DNA Damage; DNA, Neoplasm; Drug Synergism; Epirubicin; Etoposide; Female; Humans; Mitomycin; Ovarian Neoplasms; Recombinant Proteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	1992
Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer research, 1992, Jan-15, Volume: 52, Issue:2 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance; Female; Gene Expression; Genes, myc; Glutathione; Glutathione Transferase; Humans; In Vitro Techniques; Irinotecan; Membrane Glycoproteins; Ovarian Neoplasms; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured	1992
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:6 Topics: Antibiotics, Antineoplastic; Camptothecin; Cell Line; Cisplatin; DNA Topoisomerases, Type I; Drug Interactions; Etoposide; Female; Humans; Naphthoquinones; Novobiocin; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured	1990
[Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay]. Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:5 Pt 1 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Female; Irinotecan; Ovarian Neoplasms; Tumor Stem Cell Assay	1987